ICON Public Limited Company (ICLR:NASDAQ) closed at $194.65 on November 13, 2026, down 2.92% on the day. The stock trades 11.1% below its 52-week high of $219.04 and 192.4% above its 52-week low of $66.57. Over the past year, it gained 20.0%. ICON Public Limited Company is part of the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch).
In 252 trading sessions since November 13, 2025, ICLR closed higher on 129 days (51%). Its best day was October 28, 2026 (+17.04%) and its worst was February 12, 2026 (-39.85%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 2 times.
ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. Its clinical development services comprise product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. The company's clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial,...
Find more stocks like ICLR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.